LU92871I2 - Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera) - Google Patents

Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera) Download PDF

Info

Publication number: LU92871I2
Authority: LU; Luxembourg
Prior art keywords: tecfidera; pharmaceutically acceptable; acceptable derivatives; dimethyl fumarate; fumarate
Prior art date: 2004-10-08

Application number

LU92871C

Other languages

English (en)

French (fr)

Other versions

LU92871I9 (pl

Original Assignee

Forward Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-08

Filing date

2015-11-13

Publication date

2016-01-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50726313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92871(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-11-13 Application filed by Forward Pharma As filed Critical Forward Pharma As

2015-11-13 Priority to LU92871C priority Critical patent/LU92871I2/xx

2016-01-13 Publication of LU92871I2 publication Critical patent/LU92871I2/xx

2019-02-27 Publication of LU92871I9 publication Critical patent/LU92871I9/fr

Links

LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title 2
229960004419 dimethyl fumarate Drugs 0.000 title 1
229940121136 tecfidera Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU92871C 2004-10-08 2015-11-13 Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera) LU92871I2 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
LU92871C LU92871I2 (fr)	2004-10-08	2015-11-13	Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200401546		2004-10-08
DKPA200401736		2004-11-10
DKPA200500211		2005-02-11
DKPA200500419		2005-03-23
LU92871C LU92871I2 (fr)	2004-10-08	2015-11-13	Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)

Publications (2)

Publication Number	Publication Date
LU92871I2 true LU92871I2 (fr)	2016-01-13
LU92871I9 LU92871I9 (pl)	2019-02-27

Family

ID=50726313

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92871C LU92871I2 (fr)	2004-10-08	2015-11-13	Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)

Country Status (18)

Country	Link
US (29)	US20140099364A2 (pl)
EP (9)	EP2801354B1 (pl)
JP (5)	JP2008515822A (pl)
CY (5)	CY1113792T1 (pl)
DE (4)	DE202005022112U1 (pl)
DK (4)	DK2801354T3 (pl)
ES (5)	ES2582942T3 (pl)
FR (1)	FR15C0074I2 (pl)
HR (1)	HRP20170677T1 (pl)
HU (3)	HUE028342T2 (pl)
LT (2)	LT2801354T (pl)
LU (1)	LU92871I2 (pl)
ME (2)	ME02746B (pl)
PL (4)	PL2801355T3 (pl)
PT (4)	PT2801354T (pl)
RS (2)	RS54187B1 (pl)
SI (4)	SI1799196T1 (pl)
WO (1)	WO2006037342A2 (pl)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19853487A1 (de)	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
ITMI20110713A1 (it)	2011-04-29	2012-10-30	Bracco Imaging Spa	Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it)	2002-11-13	2004-05-14	Bracco Spa	Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
DK1663197T3 (da)	2003-09-09	2008-01-07	Fumapharm Ag	Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
SI1799196T1 (sl) *	2004-10-08	2016-10-28	Forward Pharma A/S	Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
US7981908B2 (en)	2005-05-11	2011-07-19	Vecta, Ltd.	Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en)	2005-05-11	2010-09-28	Vecta, Ltd.	Composition and methods for inhibiting gastric acid secretion
EP1940382A2 (en) *	2005-10-07	2008-07-09	Aditech Pharma AB	Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) *	2005-10-07	2007-04-19	Aditech Pharma Ab	Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20070142905A1 (en) *	2005-12-16	2007-06-21	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
WO2007078726A2 (en) *	2005-12-16	2007-07-12	Merck & Co., Inc.	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
EP2046334B1 (en)	2006-07-25	2014-05-21	Vecta Ltd.	Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
EP2653873B8 (en)	2007-02-08	2022-08-24	Biogen MA Inc.	Compositions and uses for treating Multiple Sclerosis
HUE032251T2 (en) *	2007-02-08	2017-09-28	Biogen Ma Inc	Neuroprotection in demyelinating diseases
MX2011001341A (es)	2008-08-19	2011-03-29	Xenoport Inc	Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
EP2564839B1 (en) *	2009-01-09	2016-05-11	Forward Pharma A/S	Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2379062A1 (en) *	2009-01-09	2011-10-26	Forward Pharma A/S	Pharmaceutical composition comprising one or more fumaric acid esters
HK1252751A1 (en) *	2009-01-09	2019-05-31	Fwp Ip Aps	Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP3318249A1 (en)	2009-04-29	2018-05-09	Biogen MA Inc.	Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
DK2533634T3 (en)	2010-02-12	2016-01-25	Biogen Ma Inc	NEURO PROTECTIVE demyelinating diseases
EP2544667B1 (en) *	2010-03-09	2018-11-14	Alkermes Pharma Ireland Limited	Alcohol resistant enteric pharmaceutical compositions
KR101865883B1 (ko) *	2011-04-08	2018-06-08	브라코 이미징 에스.피.에이.	3,5-디요오도-ｏ-[3-요오도페닐]-ｌ-티로신의 황산화 유도체의 제조 방법
PE20141639A1 (es)	2011-06-08	2014-11-08	Biogen Idec Inc	Proceso para preparar fumarato de dimetilo de alta pureza y cristalino
EP2782561A1 (en) *	2011-11-24	2014-10-01	Synthon BV	Controlled release particles comprising dimethyl fumarate
RU2014125430A (ru)	2011-11-24	2015-12-27	Синтон Бв	Контролируемое высвобождение частиц, содержащих диметилфумарат
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
CA2862885C (en) *	2012-02-07	2020-06-02	Biogen Ma Inc.	Pharmaceutical compositions containing dimethyl fumarate
NZ629728A (en)	2012-02-07	2016-07-29	Xenoport Inc	Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
US9597292B2 (en)	2012-08-22	2017-03-21	Xenoport, Inc.	Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2887934A1 (en)	2012-08-22	2015-07-01	XenoPort, Inc.	Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AR094277A1 (es)	2012-12-21	2015-07-22	Biogen Idec Inc	Derivados de fumarato sustituidos con deuterio
MX386935B (es)	2013-03-14	2025-03-04	Alkermes Pharma Ireland Ltd	Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en)	2013-03-24	2019-01-15	Arbor Pharmaceuticals, Llc	Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en)	2013-06-07	2014-12-11	Xenoport, Inc.	Method of making monomethyl fumarate
US9421182B2 (en)	2013-06-21	2016-08-23	Xenoport, Inc.	Cocrystals of dimethyl fumarate
CA2919381A1 (en) *	2013-08-01	2015-02-05	Xenoport, Inc.	Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2014314231A1 (en)	2013-08-26	2016-03-03	Fwp Ip Aps	Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
JP2016534133A (ja)	2013-09-06	2016-11-04	ゼノポート，インコーポレイティド	（ｎ，ｎ−ジエチルカルバモイル）メチルメチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
MY179355A (en) *	2013-12-12	2020-11-05	Almirall Sa	Pharmaceutical compositions comprising dimethyl fumarate
US10172794B2 (en)	2013-12-13	2019-01-08	Biogen Ma Inc.	Controlled release dosage form for once daily administration of dimethyl fumarate
JP6337135B2 (ja)	2014-02-24	2018-06-06	アルカーメスファーマアイルランドリミテッド	フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US10098863B2 (en)	2014-02-28	2018-10-16	Banner Life Sciences Llc	Fumarate esters
CA2939990C (en)	2014-02-28	2018-07-10	Banner Life Sciences Llc	Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en)	2014-02-28	2016-05-03	Banner Life Sciences Llc	Controlled release fumarate esters
US9636318B2 (en)	2015-08-31	2017-05-02	Banner Life Sciences Llc	Fumarate ester dosage forms
US10391160B2 (en)	2014-03-14	2019-08-27	Biogen Ma Inc.	Dimethyl fumarate and vaccination regimens
US9999672B2 (en)	2014-03-24	2018-06-19	Xenoport, Inc.	Pharmaceutical compositions of fumaric acid esters
WO2015161113A1 (en) *	2014-04-16	2015-10-22	Zynga Inc.	Systems and methods of incentivizing game play
CA2962916C (en) *	2014-10-08	2021-06-15	Banner Life Sciences Llc	Controlled release enteric soft capsules of fumarate esters
WO2016061393A1 (en)	2014-10-15	2016-04-21	Xenoport, Inc.	Fumarate compounds, pharmaceutical compositions, and methods of use
MA40985A (fr)	2014-11-17	2017-09-26	Biogen Ma Inc	Méthodes de traitement de la sclérose en plaques
MA40982A (fr) *	2014-11-19	2017-09-26	Biogen Ma Inc	Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41139B1 (fr) *	2014-12-11	2026-02-27	Laboratoires Juvise Pharmaceuticals	Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
HUE057865T2 (hu)	2014-12-11	2022-06-28	Actelion Pharmaceuticals Ltd	A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
KR102283582B1 (ko)	2014-12-23	2021-07-30	한미약품 주식회사	푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
WO2016113754A2 (en) *	2015-01-14	2016-07-21	Leiutis Pharmaceuticals Pvt, Ltd.	Novel oral dosage forms of dimethyl fumarate
IL252962B (en)	2015-02-08	2022-07-01	Alkermes Pharma Ireland Ltd	Monomethylfumarate prodrug compositions
EP3270911A4 (en) *	2015-03-17	2018-08-29	Hetero Labs Limited	Pharmaceutical compositions of dimethyl fumarate
MA41785A (fr) *	2015-03-20	2018-01-23	Biogen Ma Inc	Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
WO2016194004A1 (en) *	2015-06-01	2016-12-08	Sun Pharmaceutical Industries Ltd.	Pharmaceutical compositions of dimethyl fumarate
EA201890068A1 (ru) *	2015-06-17	2018-09-28	Байоджен Ма Инк.	Частицы диметилфумарата и фармацевтические композиции на их основе
US10213411B2 (en)	2015-08-27	2019-02-26	Vijaykumar Rajasekhar	Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en)	2015-10-07	2017-04-13	Neurovive Pharmaceutical Ab	Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
PL3407873T3 (pl) *	2016-01-28	2025-01-13	Zakłady Farmaceutyczne POLPHARMA S.A.	Sposób otrzymywania granulatu zawierającego fumaran dimetylu
US10463642B2 (en)	2016-02-01	2019-11-05	Vijaykumar Rajasekhar	Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
CA3013472A1 (en) *	2016-02-11	2017-08-17	Biogen Ma Inc.	Pharmaceutical bead formulations comprising dimethyl fumarate
CN110636838A (zh)	2017-06-23	2019-12-31	阿尔米雷尔有限公司	包含反丁烯二酸二甲酯的药物组合物
US11186556B1 (en)	2018-10-16	2021-11-30	Celgene Corporation	Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11013723B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Thiazolidinone and oxazolidinone compounds and formulations
TR201818293A2 (tr) *	2018-11-30	2020-06-22	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
RU2742745C1 (ru) *	2019-09-24	2021-02-10	Акционерное общество "Исследовательский Институт Химического Разнообразия"	Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом
WO2021142062A1 (en)	2020-01-10	2021-07-15	Banner Life Sciences Llc	Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2021144478A2 (en)	2020-05-06	2021-07-22	Imcyse Sa	Combination treatment for fumarate-related diseases
FR3122850A1 (fr) *	2021-05-11	2022-11-18	Faurecia Sièges d'Automobile	Siège de véhicule pliable
WO2022251620A1 (en)	2021-05-28	2022-12-01	Amgen Inc.	Formulations of apremilast
US20250000799A1 (en) *	2021-11-11	2025-01-02	V-Ensure Pharma Technologies Private Limited	Reconstitutable, Single Use Antidiabetic Compositions
US20250282721A9 (en) *	2021-12-23	2025-09-11	Gencaps Sàrl	Drug delivery system comprising monomethyl fumarate
CN116524199B (zh) *	2023-04-23	2024-03-08	江苏大学	一种基于PReNet渐进式网络的图像去雨方法及装置

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2764609A (en) *	1953-07-24	1956-09-25	Monsanto Chemicals	Isomerization of dialkyl maleates to dialkyl fumarates
US3078302A (en) *	1958-09-25	1963-02-19	Monsanto Chemicals	Production of dialkyl fumarates
GB1153927A (en)	1966-08-25	1969-06-04	Wilhelm Hoerrmann	Medicinal Composition Suitable For Treating Diseases Of The Retina
US4952594A (en) *	1973-06-18	1990-08-28	Mercer James B	Reagents and method for therapeutic treatment of multiple sclerosis
DE2530372A1 (de)	1975-07-08	1977-01-13	Walter Dr Schweckendiek	Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2703964A1 (de)	1975-07-08	1978-08-03	Walter Dr Schweckendiek	Pharmazeutische zubereitungen zur behandlung von psoriasis
US4145438A (en) *	1975-09-10	1979-03-20	Fisons Limited	Method for treatment of eczema or psoriasis
DE2621214C3 (de)	1976-05-13	1981-11-12	Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen	Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE2732131A1 (de)	1977-07-15	1979-01-25	Bayer Ag	Verfahren zur herstellung von seitenstaendige hydroxylgruppen aufweisenden isocyanat-polyadditionsprodukten
DE2749188C2 (de)	1977-11-03	1981-11-12	Bayer Ag, 5090 Leverkusen	Vorrichtung zum automatischen Einführen eines schnellaufenden Fadens in einen Fadenführungskanal einer Fadenbehandlungsvorrichtung
DE2840498C2 (de)	1978-09-18	1980-04-10	Walter Dr. 6700 Ludwigshafen Schweckendiek	Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
US4302440B1 (en) *	1980-07-31	1986-08-05		Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
CH664150A5 (de) *	1985-01-15	1988-02-15	Peter Paul Prof Dr Speiser	Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) *	1985-01-15	1992-09-22	Speiser Peter P	Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US4693896A (en)	1985-10-07	1987-09-15	Fmc Corporation	Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US4855305A (en)	1987-03-23	1989-08-08	Applied Medical Research	Compositions and methods of effecting contraception utilizing melatonin
DE3711155A1 (de) *	1987-04-02	1988-10-13	Bayer Ag	Verfahren zur herstellung von maleinsaeuredimethylester
IL83775A (en)	1987-09-04	1991-12-15	Dexter Chemical Corp	Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5242905A (en) *	1987-09-04	1993-09-07	Dexter Chemical Corporation	Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) *	1987-09-04	1993-05-25	Dexter Chemical Corporation	Diethyl ester of di-glycyl fumaramide
US4959389A (en)	1987-10-19	1990-09-25	Speiser Peter P	Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) *	1987-10-19	1995-06-13	Speiser; Peter P.	Pharmaceutical composition and process for the production thereof
US4911917A (en) *	1988-06-28	1990-03-27	Hauser-Kuhrts, Inc.	Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US5023245A (en) *	1987-11-10	1991-06-11	Hauser-Kuhrts, Inc.	Improved niacin formulation
US4965252A (en)	1988-06-28	1990-10-23	Hauser-Kuhrts, Inc.	Cholesterol-lowering combination compositions of guar gum and niacin
DE3834794A1 (de)	1988-10-12	1990-04-19	F Schielein	Oral zu verabreichendes mittel zur behandlung von psoriasis
US5484610A (en)	1991-01-02	1996-01-16	Macromed, Inc.	pH and temperature sensitive terpolymers for oral drug delivery
GEP19971086B (en)	1991-02-22	1997-12-02	Tillotts Pharma Ag	Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
US5246947A (en) *	1991-09-23	1993-09-21	Hoechst-Roussel Pharmaceuticals Incorporated	Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
FR2694693B1 (fr)	1992-07-28	1994-10-28	Abrax Bio Labs Sa	Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
PT621032E (pt) *	1993-04-23	2001-01-31	Novartis Ag	Dispositivo de distribuicao de libertacao controlada de farmaco
US5434185A (en)	1993-05-17	1995-07-18	The University Of Kentucky Research Foundation	Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
DE69524214T3 (de)	1994-05-06	2008-05-15	Pfizer Inc.	Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5589504A (en) *	1994-07-26	1996-12-31	Cornell Research Foundation, Inc.	Treatment of newborn jaundice
FR2725623A1 (fr)	1994-10-18	1996-04-19	Flamel Tech Sa	Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5804203A (en) *	1994-12-21	1998-09-08	Cosmederm Technologies	Topical product formulations containing strontium for reducing skin irritation
US5716625A (en)	1994-12-21	1998-02-10	Cosmederm Technologies	Formulations and methods for reducing skin irritation
US6139850A (en) *	1994-12-21	2000-10-31	Cosmederm Technologies	Formulations and methods for reducing skin irritation
EP0737471A3 (fr) *	1995-04-10	2000-12-06	L'oreal	Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
AU5787996A (en)	1995-04-19	1996-11-07	Lipoprotein Technologies, Inc.	Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
FR2749759B1 (fr) *	1996-06-17	1999-11-26	Adir	Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
WO1998004290A2 (en)	1996-07-26	1998-02-05	Perrine Susan P	Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
WO1998035666A1 (en)	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
DE19721099C2 (de) *	1997-05-20	1999-12-02	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten
NZ333474A (en) *	1998-01-02	1999-06-29	Mcneil Ppc Inc	A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
CA2318260C (en)	1998-01-22	2006-11-21	Asta Medica Ag	Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
DE19814358C2 (de)	1998-03-31	2002-01-17	Fumapharm Ag Muri	Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DK1067910T3 (da) *	1998-04-03	2004-10-04	Egalet As	Komposition med styret afgivelse
US20050220909A1 (en) *	2004-03-30	2005-10-06	Theoharides Theoharis C	Composition for protection against superficial vasodilator flush syndrome
DE19839566C2 (de)	1998-08-31	2002-01-17	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) *	1998-10-20	2002-01-17	Fumapharm Ag Muri	Fumarsäure-Mikrotabletten
DE19853487A1 (de) *	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
KR100297705B1 (ko) *	1999-03-29	2001-10-29	김덕중	낮은 온저항과 높은 항복전압을 갖는 전력용 반도체소자
US6537584B1 (en) *	1999-11-12	2003-03-25	Macromed, Inc.	Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) *	2000-01-10	2001-07-26	Fumapharm Ag Muri	Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
KR20010112941A (ko) *	2000-02-15	2001-12-22	오하시 미츠오	푸마르산에스테르류의 제조방법
IL151299A0 (en) *	2000-02-16	2003-04-10	Brigham & Womens Hospital	Aspirin-triggered lipid mediators
IT1317042B1 (it) *	2000-06-14	2003-05-26	Biosalts Srl	Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
EP1172101A1 (en) *	2000-06-20	2002-01-16	Helsinn Healthcare S.A.	The use of nimesulide for the treatment of psoriasis and psoriatic arthritis
AU2001271824A1 (en) *	2000-07-05	2002-01-14	Johns Hopkins School Of Medicine	Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
WO2002032374A2 (en) *	2000-10-18	2002-04-25	Immunex Corporation	Methods for treating il-18 mediated disorders
DE10101307A1 (de)	2001-01-12	2002-08-01	Fumapharm Ag Muri	Fumarsäurederivate als NF-kappaB-Inhibitor
CA2776023A1 (en)	2001-01-12	2002-07-18	Fumapharm Ag	Fumaric acid amides
SE0100200D0 (sv)	2001-01-24	2001-01-24	Astrazeneca Ab	New film coating
ES2739852T3 (es)	2001-07-06	2020-02-04	Veloxis Pharmaceuticals As	Aglomeración controlada
NO20014746D0 (no)	2001-09-28	2001-09-28	Clas M Kjoelberg	Smertelindrende middel
US7206276B2 (en) *	2001-10-12	2007-04-17	Konica Corporation	Objective lens, optical element, optical pick-up apparatus and optical information recording and/or reproducing apparatus equipped therewith
US20030152622A1 (en)	2001-10-25	2003-08-14	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral diuretic
MXPA04004476A (es)	2001-11-13	2004-08-11	Pharmacia Corp	Forma de dosificacion oral de un profarmaco la sulfonamida.
JP3796165B2 (ja) *	2001-11-20	2006-07-12	株式会社クラレ	癒着防止材
US6613800B1 (en) *	2001-12-03	2003-09-02	Steven A. Smith	Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
KR100540035B1 (ko)	2002-02-01	2005-12-29	주식회사 태평양	다단계 경구 약물 방출 제어 시스템
PT1485078E (pt)	2002-03-15	2013-01-14	Cypress Bioscience Inc	Milnacipran para o tratamento do síndrome do intestino irritável
DE10214031A1 (de)	2002-03-27	2004-02-19	Pharmatech Gmbh	Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
US20030185915A1 (en) *	2002-03-28	2003-10-02	Jaime Carlo	Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor
DE10217314A1 (de) *	2002-04-18	2003-11-13	Fumapharm Ag Muri	Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US20040038904A1 (en) *	2002-05-21	2004-02-26	Angela Ogden	Method of treating multiple sclerosis
US20030219456A1 (en) *	2002-05-21	2003-11-27	Taing Ok	Method of utilization of zygosaccharomyces rouxii
US6830759B2 (en)	2002-06-28	2004-12-14	Ajinomoto Co., Inc.	Antidiabetic preparation for oral administration
DE60305053T2 (de)	2002-08-19	2006-08-31	Glaxo Group Ltd., Greenford	Pyrimidinderivate als selektive cox-2-inhibitoren
ES2553107T3 (es)	2003-03-27	2015-12-04	Santosolve As	Composición anti-inflamatoria basada en compuestos de estroncio
US20060216358A1 (en)	2003-05-07	2006-09-28	Christian Hansen	Controlled release composition containing a strontium salt
PT1534305E (pt)	2003-05-07	2007-02-28	Osteologix As	Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
PT1622630E (pt)	2003-05-07	2012-10-11	Osteologix As	Combinações de estrôncio para a profilaxia/tratamento de patologias da cartilagem e/ou do osso
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CN1819821B (zh)	2003-08-08	2010-10-13	拜奥维尔实验室国际股份有限公司	盐酸安非他酮的改良释放片剂
DK1663197T3 (da) *	2003-09-09	2008-01-07	Fumapharm Ag	Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
AU2005231145B8 (en)	2004-03-31	2010-11-11	Bpsi Holdings, Inc.	Enteric coatings for orally ingestible substrates
TW200603792A (en)	2004-04-23	2006-02-01	Pharmacia & Upjohn Co Llc	Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
CN1245873C (zh)	2004-08-21	2006-03-22	王立峰	富马酸二甲酯微胶囊及其制备方法
CN101056624A (zh)	2004-10-08	2007-10-17	Adi技术制药股份公司	包含富马酸酯的控释药物组合物
SI1799196T1 (sl)	2004-10-08	2016-10-28	Forward Pharma A/S	Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
US20080004344A1 (en) *	2004-11-10	2008-01-03	Aditech Pharma Ab	Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1812374A1 (en)	2004-11-10	2007-08-01	Aditech Pharma AB	Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
DE102005022845A1 (de) *	2005-05-18	2006-11-23	Fumapharm Ag	Thiobernsteinsäurederivate und deren Verwendung
US20070071819A1 (en) *	2005-05-30	2007-03-29	Kesarwani Amit K	Multiple unit modified release compositions of carbamazepine and process for their preparation
AU2006265113A1 (en)	2005-07-01	2007-01-11	The Johns Hopkins University	Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20080227847A1 (en) *	2005-07-07	2008-09-18	Aditech Pharma Ab	Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
WO2007006308A1 (en)	2005-07-07	2007-01-18	Aditech Pharma Ab	Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
WO2007042034A1 (en)	2005-10-07	2007-04-19	Aditech Pharma Ab	Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP1940382A2 (en) *	2005-10-07	2008-07-09	Aditech Pharma AB	Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
EP1994168A4 (en) *	2006-02-15	2009-05-27	Md Bioalpha Co Ltd	METHOD FOR CONTROLLING THE NAD (P) / NAD (P) H RATIO WITH OXIDOREDUCTASE
WO2007148744A1 (ja)	2006-06-21	2007-12-27	Santen Pharmaceutical Co., Ltd.	フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
MX2009002299A (es)	2006-09-01	2009-03-20	Cv Therapeutics Inc	Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio.
EP2653873B8 (en) *	2007-02-08	2022-08-24	Biogen MA Inc.	Compositions and uses for treating Multiple Sclerosis
HUE032251T2 (en)	2007-02-08	2017-09-28	Biogen Ma Inc	Neuroprotection in demyelinating diseases
WO2008102855A1 (ja) *	2007-02-21	2008-08-28	Mochida Pharmaceutical Co., Ltd.	軟骨疾患治療用組成物
JPWO2008129698A1 (ja)	2007-04-12	2010-07-22	パナソニック株式会社	電源システムおよび組電池の充電方法
RU2009141539A (ru)	2007-04-25	2011-05-27	Тева Фармасьютикал Индастриес Лтд. (Il)	Комплекс фармацевтического наполнителя
US20080274182A1 (en)	2007-05-03	2008-11-06	Regina Helena Alida Boekema	Tablet coatings made from modified carboxymethylcellulose materials
WO2009005803A1 (en)	2007-07-01	2009-01-08	Joseph Peter Habboushe	Combination tablet with chewable outer layer
KR20090028047A (ko) *	2007-09-13	2009-03-18	경북대학교 산학협력단	디메틸푸마레이트의 신규 용도
CN101318901A (zh)	2008-06-17	2008-12-10	健雄职业技术学院	一种富马酸二甲酯的合成新工艺
MX2011001341A (es) *	2008-08-19	2011-03-29	Xenoport Inc	Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
JP5420877B2 (ja) *	2008-10-07	2014-02-19	テイカ製薬株式会社	眼科用剤
EP2379062A1 (en)	2009-01-09	2011-10-26	Forward Pharma A/S	Pharmaceutical composition comprising one or more fumaric acid esters
EP2564839B1 (en)	2009-01-09	2016-05-11	Forward Pharma A/S	Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
CN101475477A (zh)	2009-01-23	2009-07-08	上海化学试剂研究所	反丁烯二酸二甲酯的制备方法
US20120020954A1 (en) *	2009-03-30	2012-01-26	Anat Achiron	Methods of predicting clinical course and treating multiple sclerosis
EP3318249A1 (en) *	2009-04-29	2018-05-09	Biogen MA Inc.	Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
CN101701943A (zh)	2009-11-05	2010-05-05	宁波中普检测技术服务有限公司	气相色谱-质谱联用测定产品中富马酸二甲酯的方法
DK2533634T3 (en)	2010-02-12	2016-01-25	Biogen Ma Inc	NEURO PROTECTIVE demyelinating diseases
EP2544695B1 (en) *	2010-03-11	2015-01-07	Bender Analytical Holding B.V.	Sterile alginate-based aqueous composition for medical use and process for the preparation thereof
MX2013013781A (es)	2011-05-26	2014-01-08	Biogen Idec Inc	Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina.
PE20141639A1 (es)	2011-06-08	2014-11-08	Biogen Idec Inc	Proceso para preparar fumarato de dimetilo de alta pureza y cristalino
RU2014125430A (ru)	2011-11-24	2015-12-27	Синтон Бв	Контролируемое высвобождение частиц, содержащих диметилфумарат
CA2862885C (en)	2012-02-07	2020-06-02	Biogen Ma Inc.	Pharmaceutical compositions containing dimethyl fumarate
EP2887934A1 (en)	2012-08-22	2015-07-01	XenoPort, Inc.	Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
KR102092289B1 (ko) *	2013-06-03	2020-03-23	삼성전자주식회사	전자 기기 및 이의 문서 작성 방법
US10172794B2 (en)	2013-12-13	2019-01-08	Biogen Ma Inc.	Controlled release dosage form for once daily administration of dimethyl fumarate
US9636318B2 (en)	2015-08-31	2017-05-02	Banner Life Sciences Llc	Fumarate ester dosage forms
CA2939990C (en)	2014-02-28	2018-07-10	Banner Life Sciences Llc	Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en)	2014-02-28	2018-10-16	Banner Life Sciences Llc	Fumarate esters
US9326947B1 (en)	2014-02-28	2016-05-03	Banner Life Sciences Llc	Controlled release fumarate esters
CA2962916C (en)	2014-10-08	2021-06-15	Banner Life Sciences Llc	Controlled release enteric soft capsules of fumarate esters
WO2017040272A1 (en)	2015-08-31	2017-03-09	Banner Life Sciences Llc	Fumarate ester dosage forms
KR102740598B1 (ko) *	2015-09-07	2024-12-09	모찌다 세이야쿠 가부시끼가이샤	알긴산 동결 건조 제제
WO2017151184A1 (en)	2016-02-29	2017-09-08	Banner Life Sciences Llc	Fumarate ester dosage forms
JP6320659B2 (ja) *	2016-03-14	2018-05-09	公益財団法人田附興風会	神経再生誘導材
US10523918B2 (en)	2017-03-24	2019-12-31	Samsung Electronics Co., Ltd.	System and method for depth map

2005
- 2005-10-07 SI SI200532086A patent/SI1799196T1/sl unknown
- 2005-10-07 DK DK14172390.8T patent/DK2801354T3/en active
- 2005-10-07 PT PT141723908T patent/PT2801354T/pt unknown
- 2005-10-07 ME MEP-2017-102A patent/ME02746B/me unknown
- 2005-10-07 PL PL14172398T patent/PL2801355T3/pl unknown
- 2005-10-07 EP EP14172390.8A patent/EP2801354B1/en not_active Revoked
- 2005-10-07 ES ES05789026.1T patent/ES2582942T3/es not_active Expired - Lifetime
- 2005-10-07 DE DE202005022112.0U patent/DE202005022112U1/de not_active Expired - Lifetime
- 2005-10-07 DK DK10182198.1T patent/DK2316430T3/da active
- 2005-10-07 EP EP05789026.1A patent/EP1799196B1/en not_active Revoked
- 2005-10-07 DK DK14172398.1T patent/DK2801355T3/en active
- 2005-10-07 ME MEP-2015-540A patent/ME02253B/me unknown
- 2005-10-07 SI SI200531993T patent/SI2801355T1/sl unknown
- 2005-10-07 HU HUE05789026A patent/HUE028342T2/en unknown
- 2005-10-07 JP JP2007535023A patent/JP2008515822A/ja active Pending
- 2005-10-07 DE DE14172396.5T patent/DE14172396T1/de active Pending
- 2005-10-07 EP EP18208053.1A patent/EP3470064A1/en not_active Withdrawn
- 2005-10-07 ES ES14172390.8T patent/ES2525495T3/es not_active Expired - Lifetime
- 2005-10-07 PL PL14172390T patent/PL2801354T3/pl unknown
- 2005-10-07 RS RS20150540A patent/RS54187B1/sr unknown
- 2005-10-07 EP EP16001391.8A patent/EP3093012A1/en not_active Withdrawn
- 2005-10-07 WO PCT/DK2005/000648 patent/WO2006037342A2/en not_active Ceased
- 2005-10-07 PL PL10182198T patent/PL2316430T3/pl unknown
- 2005-10-07 RS RS20170452A patent/RS55936B1/sr unknown
- 2005-10-07 SI SI200531565T patent/SI2316430T1/sl unknown
- 2005-10-07 EP EP20140172398 patent/EP2801355B1/en not_active Revoked
- 2005-10-07 SI SI200532146A patent/SI2801354T1/sl unknown
- 2005-10-07 DE DE14172398.1T patent/DE14172398T1/de active Pending
- 2005-10-07 HU HUE14172390A patent/HUE031950T2/en unknown
- 2005-10-07 PT PT10182198T patent/PT2316430E/pt unknown
- 2005-10-07 ES ES14172398.1T patent/ES2525497T3/es not_active Expired - Lifetime
- 2005-10-07 DK DK05789026.1T patent/DK1799196T3/en active
- 2005-10-07 LT LTEP14172390.8T patent/LT2801354T/lt unknown
- 2005-10-07 EP EP18204738.1A patent/EP3459532A1/en not_active Withdrawn
- 2005-10-07 ES ES14172396.5T patent/ES2523796T1/es active Pending
- 2005-10-07 EP EP10182198A patent/EP2316430B8/en not_active Revoked
- 2005-10-07 EP EP14172396.5A patent/EP2792349A3/en not_active Ceased
- 2005-10-07 PL PL05789026.1T patent/PL1799196T3/pl unknown
- 2005-10-07 US US11/576,871 patent/US20140099364A2/en not_active Abandoned
- 2005-10-07 PT PT141723981T patent/PT2801355E/pt unknown
- 2005-10-07 ES ES10182198T patent/ES2387192T3/es not_active Expired - Lifetime
- 2005-10-07 EP EP15166243.4A patent/EP2965751A1/en not_active Withdrawn
- 2005-10-07 DE DE14172390.8T patent/DE14172390T1/de active Pending
- 2005-10-07 LT LTEP05789026.1T patent/LT1799196T/lt unknown
- 2005-10-07 PT PT57890261T patent/PT1799196T/pt unknown
2012
- 2012-08-16 CY CY20121100740T patent/CY1113792T1/el unknown
- 2012-12-06 JP JP2012267572A patent/JP2013064007A/ja active Pending
2013
- 2013-08-01 US US13/957,250 patent/US20140037740A1/en not_active Abandoned
- 2013-08-01 US US13/957,220 patent/US20130316003A1/en not_active Abandoned
- 2013-08-01 US US13/957,147 patent/US20130315993A1/en not_active Abandoned
- 2013-08-01 US US13/957,117 patent/US20140037720A1/en not_active Abandoned
2014
- 2014-03-13 US US14/209,480 patent/US20170112793A2/en not_active Abandoned
- 2014-03-13 US US14/209,756 patent/US20140199393A1/en not_active Abandoned
- 2014-03-13 US US14/209,651 patent/US20140200273A1/en not_active Abandoned
- 2014-03-13 US US14/209,823 patent/US20150024049A1/en not_active Abandoned
- 2014-03-13 US US14/209,712 patent/US20140199386A1/en not_active Abandoned
- 2014-03-13 US US14/209,584 patent/US20140200272A1/en not_active Abandoned
- 2014-03-14 US US14/212,685 patent/US20140199392A1/en not_active Abandoned
- 2014-03-14 US US14/213,673 patent/US20140199388A1/en not_active Abandoned
- 2014-03-14 US US14/213,399 patent/US20140205659A1/en not_active Abandoned
- 2014-03-14 US US14/213,321 patent/US20140199387A1/en not_active Abandoned
- 2014-03-14 US US14/212,503 patent/US20140199390A1/en not_active Abandoned
2015
- 2015-07-13 JP JP2015139809A patent/JP2015227350A/ja active Pending
- 2015-08-04 CY CY20151100679T patent/CY1116599T1/el unknown
- 2015-11-09 FR FR15C0074C patent/FR15C0074I2/fr active Active
- 2015-11-13 LU LU92871C patent/LU92871I2/xx unknown
- 2015-11-18 HU HUS1500057C patent/HUS1500057I1/hu unknown
- 2015-11-19 CY CY2015045C patent/CY2015045I2/el unknown
2016
- 2016-08-30 CY CY20161100847T patent/CY1117937T1/el unknown
2017
- 2017-04-28 US US15/581,966 patent/US20170231941A1/en not_active Abandoned
- 2017-05-04 HR HRP20170677TT patent/HRP20170677T1/hr unknown
- 2017-05-08 CY CY20171100493T patent/CY1118887T1/el unknown
- 2017-10-10 US US15/728,872 patent/US20180028483A1/en not_active Abandoned
- 2017-12-07 US US15/834,870 patent/US20180098957A1/en not_active Abandoned
2018
- 2018-02-02 JP JP2018017332A patent/JP2018087220A/ja active Pending
- 2018-05-24 US US15/988,628 patent/US20180263947A1/en not_active Abandoned
- 2018-07-26 US US16/046,509 patent/US20180325855A1/en not_active Abandoned
- 2018-11-29 US US16/204,403 patent/US20190091191A1/en not_active Abandoned
- 2018-11-29 US US16/204,503 patent/US20190091192A1/en not_active Abandoned
- 2018-11-29 US US16/204,559 patent/US20190091193A1/en not_active Abandoned
- 2018-12-20 US US16/227,287 patent/US11229619B2/en not_active Expired - Fee Related
2019
- 2019-03-06 US US16/294,038 patent/US20190201368A1/en not_active Abandoned
- 2019-05-20 JP JP2019094350A patent/JP6896792B2/ja not_active Expired - Fee Related
- 2019-07-29 US US16/525,392 patent/US11052062B2/en not_active Expired - Fee Related
2021
- 2021-02-25 US US17/185,600 patent/US20210220318A1/en not_active Abandoned
- 2021-12-16 US US17/553,367 patent/US20220105064A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY2015045I1 (el)	2016-08-31
EP2792349A3 (en)	2014-12-17
WO2006037342A3 (en)	2006-07-20
US20190201368A1 (en)	2019-07-04
PT2801355E (pt)	2015-09-18
US20210220318A1 (en)	2021-07-22
PL2801355T3 (pl)	2015-10-30
US20140199390A1 (en)	2014-07-17
PL2801354T3 (pl)	2017-08-31
JP2019147832A (ja)	2019-09-05
EP2965751A1 (en)	2016-01-13
US20160271093A2 (en)	2016-09-22
US20180098957A1 (en)	2018-04-12
US20090304790A1 (en)	2009-12-10
EP2801355A1 (en)	2014-11-12
US20140200272A1 (en)	2014-07-17
US20150024049A1 (en)	2015-01-22
HRP20170677T1 (hr)	2017-09-08
DE202005022112U1 (de)	2014-04-24
ES2523796T1 (es)	2014-12-01
JP2013064007A (ja)	2013-04-11
DK2801354T3 (en)	2017-05-15
HUE028342T2 (en)	2016-12-28
JP2008515822A (ja)	2008-05-15
EP3459532A1 (en)	2019-03-27
PL1799196T3 (pl)	2016-12-30
EP2316430A1 (en)	2011-05-04
ES2525497T3 (es)	2015-10-09
US20130315993A1 (en)	2013-11-28
PT1799196T (pt)	2016-08-31
US20180263947A1 (en)	2018-09-20
HUE031950T2 (en)	2017-08-28
US20140205659A1 (en)	2014-07-24
US20130316003A1 (en)	2013-11-28
SI2316430T1 (sl)	2012-09-28
RS54187B1 (sr)	2015-12-31
DE14172390T1 (de)	2014-12-31
US20140199392A1 (en)	2014-07-17
HK1108836A1 (zh)	2008-05-23
EP2792349A2 (en)	2014-10-22
EP2801354B1 (en)	2017-02-08
SI2801355T1 (sl)	2015-09-30
CY1113792T1 (el)	2016-07-27
US20140193495A1 (en)	2014-07-10
JP2015227350A (ja)	2015-12-17
DE14172398T1 (de)	2015-01-08
EP2316430B8 (en)	2012-07-11
US11052062B2 (en)	2021-07-06
CY2015045I2 (el)	2016-08-31
EP2316430B1 (en)	2012-06-06
US20140199386A1 (en)	2014-07-17
US20190091191A1 (en)	2019-03-28
RS55936B1 (sr)	2017-09-29
US20140099364A2 (en)	2014-04-10
US20190117613A1 (en)	2019-04-25
SI1799196T1 (sl)	2016-10-28
EP3470064A1 (en)	2019-04-17
ES2525495T3 (es)	2017-07-26
US20190343787A1 (en)	2019-11-14
HUS1500057I1 (hu)	2016-04-28
EP3093012A1 (en)	2016-11-16
US20140037720A1 (en)	2014-02-06
US20220105064A1 (en)	2022-04-07
PT2316430E (pt)	2012-06-26
LU92871I9 (pl)	2019-02-27
US20140199387A1 (en)	2014-07-17
US20170014367A2 (en)	2017-01-19
ES2525497T1 (es)	2014-12-23
US20170231941A1 (en)	2017-08-17
WO2006037342A2 (en)	2006-04-13
CY1116599T1 (el)	2016-08-31
JP2018087220A (ja)	2018-06-07
US20170112793A2 (en)	2017-04-27
US20140200273A1 (en)	2014-07-17
ES2582942T3 (es)	2016-09-16
DK2316430T3 (da)	2012-07-23
DE14172396T1 (de)	2015-01-08
LT2801354T (lt)	2017-06-26
ME02746B (me)	2018-01-20
US11229619B2 (en)	2022-01-25
EP1799196A2 (en)	2007-06-27
CY1118887T1 (el)	2018-01-10
US20180325855A1 (en)	2018-11-15
JP6896792B2 (ja)	2021-06-30
DK2801355T3 (en)	2015-07-06
LT1799196T (lt)	2016-09-12
PT2801354T (pt)	2017-06-05
PL2316430T3 (pl)	2012-11-30
SI2801354T1 (sl)	2017-07-31
US20140037740A1 (en)	2014-02-06
EP1799196B1 (en)	2016-06-22
FR15C0074I2 (fr)	2016-04-22
ES2525495T1 (es)	2014-12-23
EP2801355B1 (en)	2015-05-20
US20140199388A1 (en)	2014-07-17
ME02253B (me)	2015-12-31
CY1117937T1 (el)	2017-05-17
EP2801354A1 (en)	2014-11-12
US20160136125A2 (en)	2016-05-19
ES2387192T3 (es)	2012-09-17
FR15C0074I1 (pl)	2015-12-25
DK1799196T3 (en)	2016-08-15
US20180028483A1 (en)	2018-02-01
US20190091192A1 (en)	2019-03-28
US20190091193A1 (en)	2019-03-28
US20140199393A1 (en)	2014-07-17

Publication	Publication Date	Title
LU93093I2 (fr)	2016-08-01	Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU93189I2 (fr)	2016-10-31	Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU92517I2 (fr)	2014-10-13	Delamanide et ses dérivés pharmaceutiquement acceptables
LUC00127I2 (fr)	2020-10-06	Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92326I2 (fr)	2014-02-05	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92336I2 (fr)	2014-02-17	Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU93096I2 (fr)	2016-08-01	Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU92419I2 (fr)	2014-06-02	Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU92381I2 (fr)	2014-04-28	Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91882I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
IS2599B (is)	2010-04-15	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
LU91883I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
NO2013007I2 (no)	2013-04-12	Dapagliflozin og farmasøytisk akseptable salter derav
IS7872A (is)	2005-05-30	Pýrrólópýrimidín afleiður
LU91624I2 (fr)	2010-01-25	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
ATE438628T1 (de)	2009-08-15	Pyridazinderivate
EP1718667A4 (en)	2009-04-08	HETEROCYCLIC, SELF-ACCIDENT LINKERS AND CONJUGATES
LU92024I2 (fr)	2012-08-20	Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
DE602004026719D1 (de)	2010-06-02	Ür tablette
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
ATE460418T1 (de)	2010-03-15	Heterocyclocarboxamidderivate
ATE450506T1 (de)	2009-12-15	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate